Pulmonary Hypertension, Hypoxia and Sickle Cell Disease

This study has been completed.
Sponsor:
Information provided by:
National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier:
NCT00495638
First received: June 30, 2007
Last updated: March 14, 2014
Last verified: January 2014
  Purpose

The study will look at the risk factors for pulmonary hypertension (high blood pressure in the lungs) in children and adolescents with sickle cell anemia (SCA) and examine the role of hypoxia (oxygen shortage) in the disease. In patients with SCA, red blood cells become sickle-shaped and tend to form clumps that get stuck in blood vessels, blocking blood flow to the limbs and organs. Blocked blood vessels can cause pain, serious infections, and organ damage. Many patients with SCA also develop pulmonary hypertension.

Children and adolescents with SCA or Chuvash polycythemia (another blood disorder that carries an increased risk for pulmonary hypertension) may be eligible for this study.

Participants undergo the following procedures at the beginning (baseline) and end of the study:

  • History, physical examination and blood tests .
  • Echocardiography (ultrasound study of heart function).
  • Transcranial doppler (brain ultrasound study to measure brain blood flow).
  • Lung function tests.
  • 6-minute walk (measure of the distance covered in 6 minutes of walking).

In addition, patients are followed by telephone or by clinic visits every 6 months for a review of their medical history and medications. A physical examination is also done at 12 months.


Condition
Chuvash Polycythemia
Cerebrovascular Disease
Pulmonary Hypertension
Sickle Cell Anemia

Study Type: Observational
Official Title: Pulmonary Hypertension and the Hypoxic Response in SCD

Resource links provided by NLM:


Further study details as provided by National Institutes of Health Clinical Center (CC):

Enrollment: 29
Study Start Date: June 2007
Detailed Description:

The research is designed to determine the prevalence and risk factors of pulmonary hypertension (PHT) in children and adolescents with sickle cell disease (SCD), and to determine the role of the hypoxic response in its pathogenesis. In this regard, proliferative vascular responses mediated by (i) hypoxia inducible factor (HIF)-regulated pathways and (ii) nitric oxide (NO)-scavenging will be compared between patients with SCD and patients with Chuvash polycythemia (CP), another hematological disorder characterized by increased risk for PHT. High throughput microarray and genotyping technologies will be employed to identify candidate gene pholymorphisms involved in pathologic responses to hypoxia in SCD and CP patients with and without PHT.

  Eligibility

Ages Eligible for Study:   3 Years to 20 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria
  • INCLUSION CRITERIA

A. For PAH in children and adolescents with SCD:

Inclusion criteria for all participants:

  1. The informed consent has been signed by the participant, parent or legal guardian as appropriate.
  2. Age of 3 to 20 years.

Inclusion criteria for SCD patients:

  1. Diagnosis of sickle cell disease (electrophoretic HPLC documentation of SS, SC, Sb thalassemia or other major sickling phenotype such as SD, SO-Arab or SLepore is required).
  2. At least three weeks has elapsed since hospitalization for acute chest syndrome, pain crisis, infection or other complication of SCD.
  3. Absence of acute infection, pain crisis, or other acute complication of SCD. (Chronic SCD complications such as stuttering priapism, stable chronic pain and leg ulcers are not reasons for exclusion.)

Inclusion criteria for control participants:

  1. Self-described race is African American.
  2. Absence of diagnosis of SCD as defined above and subsequent electrophoretic or HPLC documentation.
  3. Absence of acute infection, injury, surgery or asthmatic episode.

EXCLUSION CRITERIA:

Exclusion criteria for all participants:

  1. Age of less than 3 years or 21 years or more at time of enrollment.
  2. Presence of acute infection, pain crisis, injury, surgery, asthmatic episode or other acute complication.

Exclusion criteria for SCD patients:

  1. Hemoglobin A only phenotype, hemoglobin S trait or hemoglobin C trait.
  2. Less than three weeks has elapsed since hospitalization for acute chest syndrome, pain crisis, infection or other complication of SCD.

Exclusion criteria for control participants:

  1. Self-described ethnicity other than African American.
  2. Diagnosis of SCD or electrophoretic or HPLC documentation of major sickling phenotype as described above.

B. Angiogenic and vasomotor responses mediated by HIF-regulated pathways in patients with SCD and CP with and without PAH.

INCLUSION CRITERIA:

Inclusion criteria for all participants:

  1. The informed consent has been signed by the participant, parent or legal guardian as appropriate.
  2. Age of 3 years or greater.
  3. Absence of acute infection, pain crisis, cerebral vascular accident, thrombosis or other acute complication.

Inclusion criteria for SCD or CP patients with PAH:

  1. Diagnosis of SCD and electrophoretic or HPLC documentation of SS, SC, Sbeta thalassemia or other major sickling phenotype such as SD, SO-Arab or SLepore OR diagnosis of CP and evidence of homozygosity for mutation of the von Hippel-Lindau gene at position 598 from cytosine to thymidine.
  2. At least three weeks has elapsed since hospitalization for SCD (acute chest syndrome, pain crisis, infection or other complication) or CP (cerebral vascular accident, thrombotic event or other complication).
  3. ECHO-determined TRV of 2.5 m/sec or greater.

Inclusion criteria for SCD or CP patients without PAH:

  1. Diagnosis of SCD and electrophoretic or HPLC documentation of SS, SC, Sb thalassemia or other major sickling phenotype such as SD, SO-Arab or SLepore OR diagnosis of CP and evidence of homozygosity for mutation of the von Hippel-Lindau gene at position 598 from cytosine to thymidine.
  2. At least three weeks has elapsed since hospitalization for SCD (acute chest syndrome, pain crisis, infection or other complication) or CP (cerebral vascular accident, thrombotic event or other complication).
  3. ECHO-determined TRV less than 2.5 m/sec.
  4. Matched by age (plus or minus 2 years), sex and ethnicity to a specific patient with SCD and PAH or CP and PAH enrolled for this same study.

Inclusion criteria for control participants:

  1. Absence of diagnosis of SCD as defined above and subsequent electrophoretic documentation.
  2. Absence of diagnosis of CP and subsequent documentation of VHL 598 wildtype.
  3. At least three weeks has elapsed since hospitalization for illness or surgery.
  4. Matched by age (plus or minus 2 years) and sex and ethnicity to a specific patient with SCD and PAH or CP and PAH enrolled for this same study.
  5. Absence of diagnosis of PAH, anemia, or polycythemia.

EXCLUSION CRITERIA:

Exclusion criteria for all participants:

  1. Age of less than 3 years.
  2. Presence of a condition associated with secondary PAH other than SCD or CP, such as collagen vascular disease, congenital heart disease, or chronic lung disease.
  3. Presence of acute infection, injury, surgery, asthmatic episode, pain crisis, cerebral vascular accident, thrombosis or other acute complication.

Exclusion criteria for SCD or CP patients with PAH:

  1. Hemoglobin AA only phenotype, hemoglobin S trait, hemoglobin C trait for mutation of the von Hippel-Lindau gene at position 598 from cytosine to thymidine heterozygosity or VHL wildtype.
  2. Less than three weeks has elapsed since hospitalization for SCD (acute chest syndrome, pain crisis, infection or other complication) or CP (cerebral vascular accident, thrombotic event or other complication).
  3. ECHO-determined TRV less than 2.5 m/sec.

Exclusion criteria for SCD or CP patients without PAH:

  1. Hemoglobin AA only phenotype, hemoglobin S trait, hemoglobin C trait OR for mutation of the von Hippel-Lindau gene at position 598 from cytosine to thymidine heterozygosity or VHL wildtype.
  2. Less than three weeks has elapsed since hospitalization for SCD (acute chest syndrome, pain crisis, infection or other complication) or CP (cerebral vascular accident, thrombotic event or other complication).
  3. ECHO-determined TRV greater than or equal to 2.5 m/sec.

Exclusion criteria for control participants:

  1. Diagnosis of SCD or electrophoretic or HPLC evidence of major sickling phenotype as described above OR diagnosis of CP or for mutation of the von Hippel-Lindau gene at position 598 from cytosine to thymidine homozygosity.
  2. ECHO-determined TRV greater than or equal to 2.5 m/sec.

C. High throughput microarray and genotyping technologies to identify candidate gene polymorphisms involved in pathologic responses to hypoxia in SCD and CP patients with PAH.

INCLUSION CRITERIA:

Inclusion criteria for all participants:

  1. The informed consent has been signed by the participant, parent or legal guardian as appropriate.
  2. Age of 3 years or greater.
  3. Absence of acute infection, pain crisis, cerebral vascular accident, thrombosis or other acute complication.

Inclusion criteria for SCD or CP patients with PAH:

  1. Diagnosis of SCD and electrophoretic or HPLC documentation of SS, SC, Sb thalassemia or other major sickling phenotype such as SD, SO-Arab or SLepore OR diagnosis of CP and evidence of homozygosity for mutation of the von Hippel-Lindau gene at position 598 from cytosine to thymidine.
  2. At least three weeks has elapsed since hospitalization for SCD (acute chest syndrome, pain crisis, infection or other complication) or CP (cerebral vascular accident, thrombotic event or other complication).
  3. ECHO-determined TRV of 2.5 m/sec or greater.

Inclusion criteria for SCD or CP patients without PAH:

  1. Diagnosis of SCD and electrophoretic or HPLC documentation of SS, SC, Sb thalassemia or other major sickling phenotype such as SD, SO-Arab or SLepore OR diagnosis of CP and evidence of homozygosity for mutation of the von Hippel-Lindau gene at position 598 from cytosine to thymidine.
  2. At least three weeks has elapsed since hospitalization for SCD (acute chest syndrome, pain crisis, infection or other complication) or CP (cerebral vascular accident, thrombotic event or other complication).
  3. ECHO-determined TRV less than 2.5 m/sec
  4. Matched by age (plus or minus 2 years), sex and ethnicity to a specific patient with SCD and PAH or CP and PAH enrolled for this same study.

Inclusion criteria for screening for population prevalence of polymorphisms:

  1. Absence of diagnosis of SCD, CP or PAH.
  2. Self-described African-American or Chuvash ethnicity.

EXCLUSION CRITERIA:

Exclusion criteria for all participants:

  1. Age of less than 3 years.
  2. Presence of acute infection, injury, surgery, asthmatic episode, pain crisis, cerebral vascular accident, thrombosis or other acute complication.

Exclusion criteria for SCD or CP patients with PAH:

  1. Hemoglobin AA only phenotype, hemoglobin S trait, hemoglobin C trait OR for mutation of the von Hippel-Lindau gene at position 598 from cytosine to thymidine heterozygosity or VHL wildtype.
  2. Presence of a condition associated with secondary PAH other than SCD or CP, such as collagen vascular disease, congenital heart disease, or chronic lung disease.
  3. Less than three weeks has elapsed since hospitalization for SCD (acute chest syndrome, pain crisis, infection or other complication) or CP (cerebral vascular accident, thrombotic event or other complication).
  4. ECHO-determined TRV less than 2.5 m/sec.

Exclusion criteria for SCD or CP patients without PAH:

  1. Hemoglobin AA only phenotype, hemoglobin S trait, hemoglobin C trait OR for mutation of the von Hippel-Lindau gene at position 598 from cytosine to thymidine heterozygosity or VHL wildtype.
  2. Presence of a condition associated with secondary PAH other than SCD or CP, such as collagen vascular disease, congenital heart disease, or chronic lung disease.
  3. Less than three weeks has elapsed since hospitalization for SCD (acute chest syndrome, pain crisis, infection or other complication) or CP (cerebral vascular accident, thrombotic event or other complication).
  4. ECHO-determined TRV greater than or equal to 2.5 m/sec.

Exclusion criteria for screening for population prevalence of polymorphisms

  1. Diagnosis of SCD, CP or PAH.
  2. Self-described ethnicity other than African-American or Chuvash.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00495638

Locations
United States, District of Columbia
Childrens National Medical Center
Washington, District of Columbia, United States
Howard University Hospital
Washington, District of Columbia, United States, 20060
United States, Illinois
University of Chicago
Chicago, Illinois, United States, 60637
United States, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States, 20892
United States, Michigan
University of Michigan
Ann Arbor, Michigan, United States, 48109-0624
United States, Texas
Baylor College of Medicine
Houston, Texas, United States, 77030
Russian Federation
Republic Cardiac Center in Cheboksary
Chuvashia, Russian Federation
Sponsors and Collaborators
Investigators
Principal Investigator: Caterina P Minniti, M.D. National Heart, Lung, and Blood Institute (NHLBI)
  More Information

Additional Information:
No publications provided by National Institutes of Health Clinical Center (CC)

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00495638     History of Changes
Other Study ID Numbers: 070181, 07-H-0181
Study First Received: June 30, 2007
Last Updated: March 14, 2014
Health Authority: United States: Federal Government

Keywords provided by National Institutes of Health Clinical Center (CC):
6-Minute Walk
Chuvash Polycythemia
Echocardiogram
Sickle Cell Anemia
Pulmonary Function Tests
Sickle Cell Disease
SCD
Pulmonary Hypertension

Additional relevant MeSH terms:
Anemia
Anemia, Sickle Cell
Cerebrovascular Disorders
Hypertension
Hypertension, Pulmonary
Polycythemia
Hematologic Diseases
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Hemoglobinopathies
Genetic Diseases, Inborn
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases
Lung Diseases
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on July 22, 2014